Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;38(4):573-594.
doi: 10.1007/s10555-019-09819-z.

Immunotherapies for pediatric cancer: current landscape and future perspectives

Brian Hutzen  1 , Siddhi Nath Paudel  1   2 , Meisam Naeimi Kararoudi  1 , Kevin A Cassady  1   2   3   4 , Dean A Lee  1   2   3   4 , Timothy P Cripe  5   6   7   8
Affiliations
Review

Immunotherapies for pediatric cancer: current landscape and future perspectives

Brian Hutzen et al. Cancer Metastasis Rev. 2019 Dec.

Abstract

The advent of immunotherapy has revolutionized how we manage and treat cancer. While the majority of immunotherapy-related studies performed to date have focused on adult malignancies, a handful of these therapies have also recently found success within the pediatric space. In this review, we examine the immunotherapeutic agents that have achieved the approval of the US Food and Drug Administration for treating childhood cancers, highlighting their development, mechanisms of action, and the lessons learned from the seminal clinical trials that ultimately led to their approval. We also shine a spotlight on several emerging immunotherapeutic modalities that we believe are poised to have a positive impact on the treatment of pediatric malignancies in the near future.

Keywords: Bispecific antibodies; Cell-based therapies; Immune checkpoint inhibitors; Pediatric cancer; Tumor microenvironment.

PubMed Disclaimer

References

    1. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunology and Cell Biology. 2015;93(3):290–296. - PMC - PubMed
    1. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, Schlereth B, Baeuerle PA. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. Journal of Immunotherapy. 2007;30(8):798–807. - PubMed
    1. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leukemia & Lymphoma. 1995;18(5–6):385–397. - PubMed
    1. Loffler A, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098–2103. - PubMed
    1. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–977. - PubMed

Publication types

Substances